Article
Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.
Proceedings of the National Academy of Sciences of the United States of America - 5 Jan 2010
Gastaminza Pablo, Whitten-Bauer Christina, Chisari Francis V
Abstract excerpt
Over 170 million people are chronically infected by the hepatitis C virus (HCV) and at risk for dying from liver cirrhosis and hepatocellular carcinoma. Current therapy is expensive, associated with significant side effects, and often ineffective. Discovery of antiviral compounds against HCV traditionally involves a priori target identification followed by biochemical screening and confirmation in cell-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.